CN116920029B - Traditional Chinese medicine composition for treating hypertension and preparation method thereof - Google Patents
Traditional Chinese medicine composition for treating hypertension and preparation method thereof Download PDFInfo
- Publication number
- CN116920029B CN116920029B CN202210319473.2A CN202210319473A CN116920029B CN 116920029 B CN116920029 B CN 116920029B CN 202210319473 A CN202210319473 A CN 202210319473A CN 116920029 B CN116920029 B CN 116920029B
- Authority
- CN
- China
- Prior art keywords
- parts
- water
- filtrate
- decocting
- seed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 239000003814 drug Substances 0.000 title abstract description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 65
- 239000000706 filtrate Substances 0.000 claims abstract description 61
- 210000000582 semen Anatomy 0.000 claims abstract description 41
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 38
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 37
- 244000179560 Prunella vulgaris Species 0.000 claims abstract description 22
- 244000144730 Amygdalus persica Species 0.000 claims abstract description 21
- 244000274050 Platycodon grandiflorum Species 0.000 claims abstract description 19
- 235000006040 Prunus persica var persica Nutrition 0.000 claims abstract description 19
- 235000008113 selfheal Nutrition 0.000 claims abstract description 18
- 235000021028 berry Nutrition 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 240000001851 Artemisia dracunculus Species 0.000 claims abstract description 7
- 235000003092 Artemisia dracunculus Nutrition 0.000 claims abstract description 6
- 235000006751 Platycodon Nutrition 0.000 claims abstract description 6
- 229930189914 platycodon Natural products 0.000 claims abstract description 6
- 235000002991 Coptis groenlandica Nutrition 0.000 claims abstract description 4
- 240000005001 Paeonia suffruticosa Species 0.000 claims abstract description 4
- 235000003889 Paeonia suffruticosa Nutrition 0.000 claims abstract description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 21
- 229930006000 Sucrose Natural products 0.000 claims description 20
- 239000005720 sucrose Substances 0.000 claims description 20
- -1 sucrose ester Chemical class 0.000 claims description 20
- 239000008347 soybean phospholipid Substances 0.000 claims description 18
- 238000010025 steaming Methods 0.000 claims description 14
- 241000037740 Coptis chinensis Species 0.000 claims description 13
- 235000006753 Platycodon grandiflorum Nutrition 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 10
- 238000002791 soaking Methods 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 6
- 235000008658 Artemisia capillaris Nutrition 0.000 claims description 3
- 241000092668 Artemisia capillaris Species 0.000 claims description 3
- 241000218202 Coptis Species 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 33
- 210000004369 blood Anatomy 0.000 abstract description 22
- 239000008280 blood Substances 0.000 abstract description 22
- 230000036772 blood pressure Effects 0.000 abstract description 19
- 229940079593 drug Drugs 0.000 abstract description 13
- 238000001035 drying Methods 0.000 abstract description 8
- 208000004880 Polyuria Diseases 0.000 abstract description 7
- 230000035619 diuresis Effects 0.000 abstract description 7
- 230000001603 reducing effect Effects 0.000 abstract description 6
- 239000012530 fluid Substances 0.000 abstract description 4
- 230000007774 longterm Effects 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 206010059866 Drug resistance Diseases 0.000 abstract description 2
- 244000247747 Coptis groenlandica Species 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 16
- 238000001914 filtration Methods 0.000 description 14
- 210000002216 heart Anatomy 0.000 description 10
- 230000001737 promoting effect Effects 0.000 description 9
- 238000000605 extraction Methods 0.000 description 6
- 229940083466 soybean lecithin Drugs 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 206010010774 Constipation Diseases 0.000 description 4
- 241000721047 Danaus plexippus Species 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 230000003276 anti-hypertensive effect Effects 0.000 description 4
- 230000035487 diastolic blood pressure Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000004438 eyesight Effects 0.000 description 4
- 210000005229 liver cell Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 230000002040 relaxant effect Effects 0.000 description 4
- 230000035488 systolic blood pressure Effects 0.000 description 4
- 201000000736 Amenorrhea Diseases 0.000 description 3
- 206010001928 Amenorrhoea Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 235000010674 Prunella vulgaris Nutrition 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 231100000540 amenorrhea Toxicity 0.000 description 3
- 239000002220 antihypertensive agent Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 229960001597 nifedipine Drugs 0.000 description 3
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 150000003445 sucroses Chemical class 0.000 description 3
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 description 2
- 235000011446 Amygdalus persica Nutrition 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 241001071795 Gentiana Species 0.000 description 2
- 208000034507 Haematemesis Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 241000218201 Ranunculaceae Species 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 229940127088 antihypertensive drug Drugs 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- SMRPGWBDLOQHOS-UHFFFAOYSA-N 5-[4,5-dihydroxy-6-(hydroxymethyl)-3-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxy-3,4-dihydroxy-6-[[9-hydroxy-4-(hydroxymethyl)-4,6a,6b,8a,11,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1H-picen-3-yl]oxy]oxane-2-carboxylic acid Chemical compound OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(C(O)C2O)C(O)=O)OC2C(C3C(C4C(C5(CCC6(C)C(O)CC(C)(C)CC6C5=CC4=O)C)(C)CC3)(C)CC2)(C)CO)OC(CO)C(O)C1O SMRPGWBDLOQHOS-UHFFFAOYSA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 241000427159 Achyranthes Species 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 241000748223 Alisma Species 0.000 description 1
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 1
- 241000722948 Apocynum cannabinum Species 0.000 description 1
- 235000003097 Artemisia absinthium Nutrition 0.000 description 1
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 244000104272 Bidens pilosa Species 0.000 description 1
- 235000010662 Bidens pilosa Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 241001481833 Coryphaena hippurus Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 241000893536 Epimedium Species 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 235000014066 European mistletoe Nutrition 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 244000111489 Gardenia augusta Species 0.000 description 1
- 235000018958 Gardenia augusta Nutrition 0.000 description 1
- 241000305492 Gastrodia Species 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 241000218195 Lauraceae Species 0.000 description 1
- 240000007890 Leonurus cardiaca Species 0.000 description 1
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 description 1
- 241000112528 Ligusticum striatum Species 0.000 description 1
- 241000361919 Metaphire sieboldi Species 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 241001106477 Paeoniaceae Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 240000002924 Platycladus orientalis Species 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 235000015533 Prunus davidiana Nutrition 0.000 description 1
- 240000002381 Prunus davidiana Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 240000004980 Rheum officinale Species 0.000 description 1
- 235000008081 Rheum officinale Nutrition 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 244000152640 Rhipsalis cassutha Species 0.000 description 1
- 235000012300 Rhipsalis cassutha Nutrition 0.000 description 1
- BMWPBKOFJSHJAW-UHFFFAOYSA-N Saponin B Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(OC7OC(CO)C(O)C(O)C7O)C6=O)C(C)(C)C5CCC34C)C2C1)C(=O)O BMWPBKOFJSHJAW-UHFFFAOYSA-N 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 240000006079 Schisandra chinensis Species 0.000 description 1
- 235000008422 Schisandra chinensis Nutrition 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- 241000913745 Spatholobus Species 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 239000000219 Sympatholytic Substances 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- 240000000260 Typha latifolia Species 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 240000008866 Ziziphus nummularia Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 239000001138 artemisia absinthium Substances 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 210000000613 ear canal Anatomy 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000001094 effect on targets Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 235000018905 epimedium Nutrition 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- ACGDKVXYNVEAGU-UHFFFAOYSA-N guanethidine Chemical compound NC(N)=NCCN1CCCCCCC1 ACGDKVXYNVEAGU-UHFFFAOYSA-N 0.000 description 1
- 229960003602 guanethidine Drugs 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- PPRSVUXPYPBULA-UHFFFAOYSA-N saponin A Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(O)C6=O)C(C)(C)C5CCC34C)C2C1)C(=O)O PPRSVUXPYPBULA-UHFFFAOYSA-N 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 229930193195 schizandrin Natural products 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229960001288 triamterene Drugs 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/14—Cupressaceae (Cypress family), e.g. juniper or cypress
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/536—Prunella or Brunella (selfheal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the field of traditional Chinese medicines, and particularly relates to a composition for treating hypertension and a preparation method thereof. The raw materials of the composition comprise, by weight, the following components: 1-10 parts of platycladi seed, 1-5 parts of shizandra berry, 1-10 parts of rhizoma alismatis, 1-10 parts of tree peony bark, 1-10 parts of platycodon root, 1-10 parts of cassia twig, 1-5 parts of peach seed, 1-10 parts of tarragon, 1-5 parts of selfheal, 1-5 parts of coptis root and 1-10 parts of cassia seed. The preparation method comprises decocting fructus Schisandrae chinensis, semen Persicae and semen Cassiae in water, decocting the residue, alismatis rhizoma, cortex moutan, radix Platycodi, ramulus Cinnamomi, prunellae Spica and Coptidis rhizoma, and decocting herba Artemisiae Scopariae and semen Platycladi; and finally, merging, concentrating and drying the filtrate. The medicines are combined to warm yang and remove fluid, promote diuresis and clear heat, activate blood and remove blood stasis, thereby fundamentally achieving the effect of reducing blood pressure. Compared with the existing common chemical medicine, the traditional Chinese medicine composition has no toxic or side effect, multi-component, multi-target and multi-level regulation of organism, no drug resistance and suitability for long-term administration.
Description
Technical Field
The invention belongs to the technical field of preparation of traditional Chinese medicine compositions, and particularly relates to a traditional Chinese medicine composition for treating hypertension and a preparation method thereof.
Background
Hypertension (hypertension) refers to a clinical syndrome characterized by an increase in systemic arterial blood pressure (systolic and/or diastolic blood pressure) (systolic pressure. Gtoreq.140 mmHg, diastolic pressure. Gtoreq.90 mmHg), accompanied by functional or organic impairment of organs such as heart, brain, kidneys, etc.
Various factors can cause an increase in blood pressure. The ability of the heart to pump blood is enhanced (e.g., increased contractility of the heart, etc.) such that the pumping of blood per second is increased. Another factor is that the aorta loses normal elasticity and becomes stiff and does not expand effectively as the heart pumps blood, and therefore, the flow of blood pumped by each heart beat passes through a smaller space than normal, resulting in an increase in pressure. This is why hypertension occurs most often in the elderly where atherosclerosis causes the arterial wall to thicken and become stiff. Systemic arterioles can temporarily contract due to stimulation by hormones in the nerve and blood, also causing an increase in blood pressure. A third factor that may lead to an increase in blood pressure is the increase in fluid volume in the circulation. This is often the case in kidney disease where the kidneys are unable to adequately remove sodium salts and water from the body, and blood volume in the body increases, resulting in increased blood pressure.
The existing first-line medicine for treating hypertension is favorable for diuretics and antihypertensives, such as hydrochlorothiazide, triamterene, amiloride, spironolactone, furosemide and the like; sympatholytic agents such as clonidine, rimidine, safamifen, and the like; noradrenergic nerve ending blockers: such as reserpine, guanethidine, etc.; adrenergic receptor blocking agents: such as propranolol and the like; renin-angiotensin system inhibitor and calcium antagonist.
The existing antihypertensive drug can only temporarily relieve discomfort caused by the rise of blood pressure, can not radically improve the blood pressure, and can generate certain side effects. The traditional Chinese medicine for treating hypertension has the advantage of regulating blood pressure at multiple points and angles, but the traditional Chinese medicine for treating hypertension has more medicinal herbs and has an undefined effect.
For example, chinese patent application CN201610598904.8 discloses a traditional Chinese medicine for treating hypertension, which is prepared from the following traditional Chinese medicine raw materials in parts by weight: 10-25 parts of mistletoe, 5-16 parts of mulberry, 5-15 parts of ligusticum wallichii, 8-22 parts of achyranthes root, 3-12 parts of selfheal, 6-16 parts of dogbane leaf, 8-15 parts of spanishneedles herb, 3-10 parts of motherwort herb, 5-9 parts of mother-of-pearl, 5-10 parts of gastrodia tuber, 5-20 parts of kudzuvine root, 2-10 parts of radix scrophulariae, 3-12 parts of rhizoma alismatis, 3-8 parts of spina date seed, 6-14 parts of oriental wormwood, 5-12 parts of concha haliotidis, 3-15 parts of herba siegesbeckiae, 8-16 parts of earthworm, 6-12 parts of gentian, 2-8 parts of gardenia jasminoides, 3-10 parts of rhizoma anemarrhenae, 5-15 parts of cattail, 4-9 parts of pollen typhae, 5-12 parts of curculiginis, 2-8 parts of epimedium herb, 5-13 parts of notopterygium root and 5-10 parts of suberect spatholobus stem. The invention claims that the traditional Chinese medicine has the effects of activating blood circulation to dissipate blood stasis, dredging collaterals and nourishing heart, and reducing blood pressure and blood fat through reasonable collocation of traditional Chinese medicine raw materials, and is suitable for patients with hypertension to take; however, the invention has a plurality of raw materials and an undefined action mechanism. Meanwhile, excessive raw materials not only bring burden to users, but also can cause other side effects after long-term administration. Therefore, it has not been possible to universally serve a large number of hypertensive populations.
Disclosure of Invention
Aiming at the defects existing in the prior art, the invention provides a traditional Chinese medicine composition for treating hypertension. The traditional Chinese medicine has reasonable prescription, high utilization rate of medicinal materials and no toxic or side effect, and the antihypertensive effect can reach the level superior to that of the common chemical first-line antihypertensive medicine.
In order to achieve the purpose of the invention, the technical scheme adopted is as follows:
The composition for treating hypertension comprises the following raw materials in parts by weight: 1-10 parts of platycladi seed, 1-5 parts of shizandra berry, 1-10 parts of rhizoma alismatis, 1-10 parts of tree peony bark, 1-10 parts of platycodon root, 1-10 parts of cassia twig, 1-5 parts of peach seed, 1-10 parts of tarragon, 1-5 parts of selfheal, 1-5 parts of coptis root and 1-10 parts of cassia seed.
Preferably, the raw materials of the composition comprise the following components in parts by weight: 1-5 parts of platycladi seed, 1-5 parts of shizandra berry, 1-5 parts of rhizoma alismatis, 3-6 parts of moutan bark, 2-6 parts of platycodon grandiflorum, 1-5 parts of cassia twig, 1-3 parts of peach seed, 1-5 parts of artemisia capillaris, 1-3 parts of selfheal, 1-3 parts of coptis chinensis and 1-5 parts of cassia seed.
Preferably, the raw materials of the composition comprise the following components in parts by weight: 2 parts of platycladi seed, 3 parts of shizandra berry, 5 parts of rhizoma alismatis, 5 parts of moutan bark, 5 parts of platycodon grandiflorum, 3 parts of cassia twig, 2 parts of peach seed, 5 parts of herba artemisiae capillaris, 1 part of selfheal, 1 part of coptis chinensis and 4 parts of cassia seed.
Preferably, the starting materials of the composition further comprise soybean phospholipids and sucrose esters.
The efficacy of each drug is as follows:
Semen Platycladi is seed kernel of End1 of Platycladus orientalis Biotaorientalis (L.). Contains fatty oil about 14%, unsaturated fatty acid, small amount of volatile oil, saponin, protein, calcium, phosphorus, ferrum, and vitamins. Semen Platycladi is sweet in nature and taste, has the effects of nourishing heart and soothing nerves, and relaxing bowel, and is clinically used for treating palpitation, insomnia, spermatorrhea, night sweat, constipation and the like.
Fructus Schisandrae contains schizandrin, vitamin C, resin, tannin and small amount of saccharide. Has effects of astringing lung to relieve cough, nourishing and astringing essence, relieving diarrhea and arresting sweating.
Alismatis rhizoma is dry tuber of Alismatis rhizoma Alisma orientalis (Sam.) Juzep. The stem and leaf are picked up in winter when they are withered, cleaned, dried and removed from fibrous root and coarse skin. Has the effects of promoting urination and clearing damp heat, and is clinically used for treating dysuria, edema and fullness, diarrhea and oliguria, phlegm-fluid dizziness, heat stranguria and pain, and the like.
Cortex moutan is dried root bark of peony Paeonia suffruticosa Andr of Ranunculaceae. Clear heat and cool blood, activate blood and remove stasis. Can be used for treating toxic heat, speckle, hematemesis, epistaxis, night fever, early cooling, sweating, bone steaming, amenorrhea, dysmenorrhea, carbuncle, skin sore, and traumatic injury.
Radix Platycodi is dry root of radix Platycodi Platycodon grandiflorum (Jacq.) A.DC. Collected in spring and autumn, cleaned, removed fibrous root, peeled or not peeled, and dried. Disperse lung, relieve sore throat, eliminate phlegm and expel pus. Can be used for treating cough with excessive phlegm, chest distress, pharyngalgia, hoarseness, pulmonary abscess, and pyogenic infection.
Ramulus Cinnamomi is dried twig of Cinnamomum cassia Cinnamomum CASSIA PRESL belonging to Lauraceae. Induce sweat to relieve muscle, warm and unblock meridians, strengthen yang and transform qi, calm pulse and reduce qi. Can be used for treating common cold due to wind-cold, abdominal pain, amenorrhea due to blood cold, arthralgia, phlegm retention, edema, palpitation, and dolphin.
Peach kernel is a dried mature seed of Prunus persica (L.) Batsch or Prunus persica Prunus davidiana (Carr.) Franch. Promoting blood circulation, removing blood stasis, loosening bowel to relieve constipation, and can be used for treating amenorrhea, dysmenorrhea, abdominal mass, traumatic injury, constipation due to intestinal dryness.
Herba Artemisiae Scopariae is young stem and leaf of herba Artemisiae Scopariae of Compositae. Has effects of clearing heat and promoting diuresis, and can be used for treating jaundice due to damp-heat, dysuria, and itch, sore and scabies.
Prunella vulgaris is fruit ear of Prunella vulgaris Prunella v ulgaris L. Of Labiatae, mainly contains ursolic acid, oleanolic acid, caffeic acid, gallic acid, prunella vulgaris saponin A, prunella vulgaris saponin B, umbelliferone, oleic acid, etc., has cold nature, pungent and bitter taste, and has effects of clearing pathogenic fire, improving eyesight, resolving hard mass, and detumescence.
Rhizoma Coptidis is dried rhizome of rhizoma Coptidis or rhizoma Coptidis of Ranunculaceae. It enters heart, spleen, stomach, liver, gall bladder and large intestine meridians. Has effects of clearing heat, eliminating dampness, purging pathogenic fire and removing toxic substances. Can be used for treating damp-heat distention and fullness, emesis, acid regurgitation, dysentery, jaundice, high fever unconsciousness, excessive heart fire, vexation, insomnia, hematemesis, epistaxis, conjunctival congestion, toothache, diabetes, carbuncle, and furuncle; it is indicated for eczema, wet sore, suppurative ear canal, etc.
Semen Cassiae is mature seed of Cassia obatusifolial of Leguminosae, has slightly cold nature, bitter taste, sweet taste, and has effects of clearing heat, improving eyesight, loosening bowel to relieve constipation.
It is still another object of the present invention to provide a method for preparing the above composition, comprising the steps of:
(1) Decocting fructus Schisandrae chinensis, semen Persicae and semen Cassiae in water to obtain residue 1 and filtrate 1;
(2) Mixing the residue 1 with Alismatis rhizoma, cortex moutan, radix Platycodi, ramulus Cinnamomi, prunellae Spica and Coptidis rhizoma, and decocting in water to obtain filtrate 2;
(3) Decocting herba Artemisiae Scopariae and semen Platycladi in water to obtain filtrate 3;
(4) Concentrating filtrate 1, filtrate 2 and filtrate 3 to obtain concentrated solution.
Preferably, the step (1) is soaked for 20-40min before decoction; the decoction time is 0.5-1h, the decoction times are 1-2 times, and the mass ratio of the volume of water to the shizandra berry, the peach kernel and the cassia seed is 8-12:1mL/g.
Preferably, the time of the decoction in the step (2) is 1-1.5h, and the times of the decoction are 1-2 times.
Preferably, in the step (3), the herba Artemisiae Scopariae and semen Platycladi are steamed before being decocted in water, wherein the steaming time is 40-60min, and the steaming temperature is 80-90 ℃.
Preferably, soybean phospholipid and sucrose ester are added into the water in the step (2), wherein the mass ratio of the soybean phospholipid to the sucrose ester to the water is 0.005-0.01:0.001-0.003:1.
It is also an object of the present invention to provide the use of the above composition for the preparation of a product for the treatment of hypertension.
Compared with the prior art, the invention has the beneficial effects that:
(1) The invention combines the basic theory of traditional Chinese medicine, adopts scientific compatibility, wherein the tarragon has bitter taste and slight cold, enters spleen, liver and gall, and the alisma has sweet and light taste and cold property, and can promote diuresis and remove dampness, dispel heat, eliminate turbid pathogen and reduce lipid; the two herbs together induce urination, clear damp-heat and relieve edema of body, are monarch drugs (modern researches have surface that they can promote sodium excretion and reduce wall tension of blood vessels). Peach kernel has the effects of promoting blood circulation to remove blood stasis, relaxing bowel, and cortex moutan has the effects of clearing heat and cooling blood, and promoting blood circulation to remove blood stasis; the co-assisting monarch drug is a ministerial drug for clearing heat, activating blood, promoting diuresis and excreting dampness; semen cassiae has the effects of clearing heat and improving eyesight, relaxing bowel, semen platycladi with the effects of nourishing heart and soothing nerves, relaxing bowel, fructus schisandrae with the effects of astringing lung and relieving cough, nourishing and astringing essence, radix platycodi with the effects of ventilating lung and relieving sore throat, cassia twig with the effects of warming yang and promoting diuresis, coptis with the effects of clearing lung and stomach heat, selfheal with the effects of clearing heat and improving eyesight, and eliminating stagnation and detumescence, and can clear liver and gall fire. The medicines are combined to warm yang and remove fluid, promote diuresis and clear heat, activate blood and remove stasis, and regulate blood pressure on the whole. Compared with the existing common chemical medicines, the multi-component multi-target multi-level medicine can regulate the organism, has no toxic or side effect and no drug resistance, and is suitable for long-term administration.
(2) According to the invention, aiming at the problems that the effective components of the composition are complex, the extraction is incomplete, and the maximum efficacy of compatibility of the composition is not exerted, further research on the preparation method discovers that the schisandra chinensis, the peach kernel and the cassia seed are decocted, the herba artemisiae capillaris and the platycladi seed are steamed and then decocted, the extraction of the effective components is more complete, the generation of new active products of the extracting solution and the conversion of the active components are promoted, the effect of the medicine is stronger, and the blood pressure reducing efficacy is stronger than that of the combined decoction medicine.
(3) The soybean phospholipid and sucrose ester adopted by the invention not only have strong emulsifying capacity and improve the extraction rate of medicinal materials, but also can be combined with damaged liver cell membranes in a complete molecular form through synergistic effect, repair the damaged liver cell membranes and promote liver cell regeneration, and can also emulsify fat in liver into small particles in blood, so that the soybean phospholipid has the double effects of repairing the liver cell membranes and digesting fat in liver, and has good effects on fatty liver, reducing blood pressure and blood fat.
Detailed Description
The invention is further described in connection with the following detailed description.
Example 1:
The raw materials of the embodiment are as follows: 2 parts of platycladi seed, 3 parts of shizandra berry, 5 parts of rhizoma alismatis, 5 parts of moutan bark, 5 parts of platycodon grandiflorum, 3 parts of cassia twig, 2 parts of peach seed, 5 parts of herba artemisiae capillaris, 1 part of selfheal, 1 part of coptis chinensis and 4 parts of cassia seed.
The preparation method of this example is as follows:
(1) Soaking fructus Schisandrae chinensis, semen Persicae and semen Cassiae in 8 times of water for 20min, decocting for 1 hr, and filtering to obtain residue 1 and filtrate 1;
(2) Adding 8 times of water into the residue 1, the rhizoma alismatis, the moutan bark, the platycodon grandiflorum, the cassia twig, the selfheal and the coptis chinensis, adding soybean lecithin and sucrose ester into the water, decocting for 1h, decocting for 2 times, and filtering to obtain filtrate 2; wherein, the mass ratio of soybean phospholipid, sucrose ester and water is 0.005:0.001:1, a step of;
(3) Steaming herba Artemisiae Scopariae and semen Platycladi in 80 deg.C water pot for 60min, and decocting in water for 30min to obtain filtrate 3;
(4) Mixing filtrate 1, filtrate 2 and filtrate 3, concentrating to relative density of 1.2 (60deg.C), and drying.
Example 2:
4 parts of platycladi seed, 5 parts of shizandra berry, 8 parts of rhizoma alismatis, 6 parts of moutan bark, 6 parts of platycodon root, 5 parts of cassia twig, 3 parts of peach seed, 5 parts of herba artemisiae capillaries, 3 parts of selfheal, 3 parts of coptis chinensis and 5 parts of cassia seed.
The preparation method of this example is as follows:
(1) Soaking fructus Schisandrae chinensis, semen Persicae and semen Cassiae in 12 times of water for 30min, decocting for 30min, and filtering to obtain residue 1 and filtrate 1;
(2) Adding 5 times of water into the residue 1, the rhizoma alismatis, the moutan bark, the platycodon grandiflorum, the cassia twig, the selfheal and the coptis chinensis, adding soybean lecithin and sucrose ester into the water, decocting for 1h, decocting for 2 times, filtering and combining to obtain filtrate 2; wherein, the mass ratio of soybean phospholipid, sucrose ester and water is 0.006:0.002:1, a step of;
(3) Steaming herba Artemisiae Scopariae and semen Platycladi in 90 deg.C water pot for 40min, and decocting in water for 30min to obtain filtrate 3;
(4) Mixing filtrate 1, filtrate 2 and filtrate 3, concentrating to relative density of 1.2 (60deg.C), and drying.
Example 3:
The raw materials of the embodiment are as follows: 1 part of platycladi seed, 2 parts of shizandra berry, 2 parts of rhizoma alismatis, 1 part of moutan bark, 1 part of platycodon root, 2 parts of cassia twig, 1 part of peach seed, 2 parts of tarragon, 2 parts of selfheal, 2 parts of coptis chinensis and 1 part of cassia seed.
The preparation method of this example is as follows:
(1) Soaking fructus Schisandrae chinensis, semen Persicae and semen Cassiae in 10 times of water for 20min, decocting for 30min, and filtering to obtain residue 1 and filtrate 1;
(2) Adding 5 times of water into the residue 1, the rhizoma alismatis, the moutan bark, the platycodon grandiflorum, the cassia twig, the selfheal and the coptis chinensis, adding soybean lecithin and sucrose ester into the water, decocting for 1h, decocting for 2 times, and filtering to obtain filtrate 2; wherein, the mass ratio of soybean phospholipid, sucrose ester and water is 0.008:0.001:1.
(3) Steaming herba Artemisiae Scopariae and semen Platycladi in 80 deg.C water pot for 40min, and decocting in water for 30min to obtain filtrate 3;
(4) Mixing filtrate 1, filtrate 2 and filtrate 3, concentrating to relative density of 1.2 (60deg.C), and drying.
Comparative example 1
The difference between the comparative example and the example 1 is that the auxiliary materials of the prescription are different, and the prescription is prepared as follows:
2 parts of wild jujube seed, 3 parts of shizandra berry, 5 parts of rhizoma alismatis, 5 parts of moutan bark, 5 parts of platycodon root, 3 parts of cassia twig, 2 parts of peach seed, 5 parts of herba artemisiae capillaris, 1 part of baical skullcap root, 1 part of rhubarb and 4 parts of cassia seed.
The preparation method comprises the following steps:
(1) Soaking fructus Schisandrae chinensis, semen Persicae and semen Cassiae in 8 times of water for 20min, decocting for 1 hr, and filtering to obtain residue 1 and filtrate 1;
(2) Adding 8 times of water into the residue 1, the rhizoma alismatis, the moutan bark, the platycodon grandiflorum, the cassia twig, the radix scutellariae and the rheum officinale, adding soybean lecithin and sucrose ester into the water, decocting for 1h, decocting for 2 times, and filtering to obtain filtrate 2; wherein, the mass ratio of soybean phospholipid, sucrose ester and water is 0.005:0.001:1, a step of;
(3) Steaming herba Artemisiae Scopariae and semen Ziziphi Spinosae in 80deg.C water for 60min, and decocting in water for 30min to obtain filtrate 3;
(4) Mixing filtrate 1, filtrate 2 and filtrate 3, concentrating to relative density of 1.2 (60deg.C), and drying.
Comparative example 2
The comparison example is different from the example 1 in that the monarch drug and ministerial drug of the prescription are different, the prescription is prepared as follows:
2 parts of platycladi seed, 3 parts of shizandra berry, 5 parts of poria cocos, 5 parts of red paeony root, 5 parts of platycodon grandiflorum, 3 parts of cassia twig, 2 parts of peach seed, 5 parts of gentian, 1 part of selfheal, 1 part of coptis chinensis and 4 parts of cassia seed.
The preparation method comprises the following steps:
(1) Soaking fructus Schisandrae chinensis, semen Persicae and semen Cassiae in 8 times of water for 20min, decocting for 1 hr, and filtering to obtain residue 1 and filtrate 1;
(2) Adding 8 times of water into the residue 1, poria, radix Paeoniae Rubra, radix Platycodi, ramulus Cinnamomi, prunellae Spica and Coptidis rhizoma, adding soybean phospholipid and sucrose ester into the water, decocting for 1 hr, decocting for 2 times, and filtering to obtain filtrate 2; wherein, the mass ratio of soybean phospholipid, sucrose ester and water is 0.005:0.001:1, a step of;
(3) Steaming radix Gentianae and semen Platycladi in water pot at 80deg.C for 60min, and decocting in water for 30min to obtain filtrate 3;
(4) Mixing filtrate 1, filtrate 2 and filtrate 3, concentrating to relative density of 1.2 (60deg.C), and drying.
Comparative example 3
This comparative example differs from example 1 in the preparation method, specifically as follows:
(1) Soaking fructus Schisandrae chinensis, semen Persicae and semen Cassiae in 8 times of water for 20min, decocting for 1 hr, and filtering to obtain residue 1 and filtrate 1;
(2) Adding 8 times of water into the residue 1, the rhizoma alismatis, the moutan bark, the platycodon grandiflorum, the cassia twig, the selfheal and the coptis chinensis, adding sucrose ester into the water, decocting for 1h, decocting for 2 times, and filtering to obtain filtrate 2; wherein, the mass ratio of sucrose ester to water is 0.006:1, a step of;
(3) Steaming herba Artemisiae Scopariae and semen Platycladi in 80 deg.C water pot for 60min, and decocting in water for 30min to obtain filtrate 3;
(4) Mixing filtrate 1, filtrate 2 and filtrate 3, concentrating to relative density of 1.2 (60deg.C), and drying.
Comparative example 4
This comparative example differs from example 1 in the preparation method, specifically as follows:
(1) Soaking fructus Schisandrae chinensis, semen Persicae and semen Cassiae in 8 times of water for 20min, decocting for 1 hr, and filtering to obtain residue 1 and filtrate 1;
(2) Adding 8 times of water into the residue 1, the rhizoma alismatis, the moutan bark, the platycodon grandiflorum, the cassia twig, the selfheal and the coptis chinensis, adding soybean lecithin into the water, decocting for 1h, decocting for 2 times, and filtering to obtain filtrate 2; wherein, the mass ratio of soybean phospholipid to water is 0.006:1, a step of;
(3) Steaming herba Artemisiae Scopariae and semen Platycladi in 80 deg.C water pot for 60min, and decocting in water for 30min to obtain filtrate 3;
(4) Mixing filtrate 1, filtrate 2 and filtrate 3, concentrating to relative density of 1.2 (60deg.C), and drying.
Test example 1 clinical trial
Subject selection: according to the diagnosis standard of the revised edition 2018 of the Chinese hypertension control guide, 100 cases of clinical patients with hypertension are selected and divided into a positive group and an experimental group, wherein the positive group is taken by nifedipine tablets according to the method of description, the experimental group is taken by the embodiment 1 of the invention, and the dosage of each time is 36g of crude drug, and the administration is carried out three times a day before meals. The total treatment was 4 weeks.
The observation index is that the blood pressure value of the patient and subjective feelings such as headache, dizziness and sleeping are recorded before the experiment, and after the medicine taking is finished for 4 weeks, the blood pressure value of the patient is measured at 10 early morning of the next day, and the physical condition of the patient is inquired.
And (3) result judgment:
the effect is shown that the blood pressure of the patient is recovered to be normal, the diastolic pressure is reduced by 15 mmHg or more than before treatment or the systolic pressure is reduced by 25mmHg or more than before treatment, and the clinical symptoms of hypertension disappear, and the effect can be judged;
the method is effective: the diastolic pressure is reduced by 5-10 mm Hg before treatment or the systolic pressure is reduced by more than 15mmHg before treatment, and the clinical symptoms of hypertension are reduced to some extent, which can be judged to be effective;
invalidation: the blood pressure value of the patient is not obviously reduced, and headache and dizziness are not improved.
The effectiveness of the compositions of the present invention in treating patients with hypertension is evaluated as shown in Table 1.
TABLE 1
| Group of | Number of examples | Has obvious effect | Effective and effective | Invalidation of |
| Positive group | 50 | 15 | 32 | 3 |
| Experimental group | 50 | 21 | 28 | 1 |
Experimental example two pharmacodynamic experiments on hypotensive animals
The SHR 90 spontaneous hypertensive male rats were normally bred for one week and were divided into 9 groups according to a random number table, namely, examples 1 to 3 groups, comparative examples 1 to 4 groups, model groups and positive groups, each group having 10 animals. The dry extract powders prepared by the respective groups of examples 1 to 3 and comparative examples 1 to 4 were administered 10g (equivalent crude drug)/kg each time, and were administered once daily by stomach irrigation. The positive group was given 9mg/kg nifedipine daily and the model group was given equal volume of physiological saline. The results are observed 4 weeks after gastric administration, see table 2.
Table 2 effect of composition on SHR rat arterial blood pressure
| Grouping | Number of rats (Only) | Before the experiment | After the experiment | Percentage of blood pressure drop% |
| Model group | 10 | 162.1±2.9 | 157.9±3.6 | 2.50 |
| Positive group | 10 | 160.5±4.7 | 135.2±7.1# | 15.76 |
| Example 1 | 10 | 164.2±1.5 | 112.3±2.7#* | 31.61 |
| Example 2 | 10 | 163.7±2.3 | 110.9±4.4#* | 32.25 |
| Example 3 | 10 | 159.0±8.4 | 112.5±3.5#* | 29.25 |
| Comparative example 1 | 10 | 162.6±5.8 | 134.9±5.0#△ | 17.04 |
| Comparative example 2 | 10 | 160.3±6.2 | 141.2±3.8#△ | 11.92 |
| Comparative example 3 | 10 | 161.9±9.1 | 128.1±2.9#△ | 20.88 |
| Comparative example 4 | 10 | 160.8±1.6 | 134.1±2.3#△ | 16.60 |
Note that: # represents statistically significant, # P < 0.05 compared to the model group; * The expression is compared with the positive group, and has statistical significance, and P is less than 0.05; delta represents that, compared with the group of example 1, △ P < 0.05 is statistically significant.
Analysis of results:
The composition disclosed by the invention has the advantages of warming yang, resolving decoction, promoting diuresis, clearing heat, promoting blood circulation, removing blood stasis, and regulating blood pressure by virtue of multiple components and multiple targets through compatibility of the medicinal materials such as artemisia capillaris, alisma orientale and the like. Compared with the first-line antihypertensive drug, the traditional Chinese medicine has obvious treatment advantage, and has no side effect on target organs of organisms after long-term administration. According to the invention, by further researching the decoction process, the tarragon and the platycladi seed are steamed and then decocted, the shizandra berry, the peach kernel and the cassia seed are decocted separately, the soybean lecithin and the sucrose ester are added into the residues and the other medicinal herbs for extraction, the extraction of the functional components is more complete, and the medicinal effect is stronger.
Comparative example 1 and comparative example 2 use different monarch, minister, assistant and guide drugs according to the theory of traditional Chinese medicine, and the blood pressure reducing effect is inferior to that of the formula of the invention; the preparation methods of comparative examples 3-4 do not add soybean phospholipids or sucrose esters, the active ingredients of the prepared liquid medicine are not completely extracted, the blood pressure reducing effect is obviously inferior to that of the method of the invention, and the soybean phospholipids and the sucrose esters have cooperativity in the aspects of extraction and treatment effect. In conclusion, the dry paste powder prepared by the raw materials according to the preparation method of the invention has good antihypertensive effect on antihypertensive aspect, and the curative effect and safety of the dry paste powder are superior to those of nifedipine which is a chemical drug.
The foregoing detailed description is directed to one of the possible embodiments of the present invention, which is not intended to limit the scope of the invention, but is to be accorded the full scope of all such equivalents and modifications so as not to depart from the scope of the invention.
Claims (5)
1. The composition for treating hypertension is characterized by comprising the following raw materials in parts by weight: 1-10 parts of platycladi seed, 1-5 parts of shizandra berry, 1-10 parts of rhizoma alismatis, 1-10 parts of tree peony bark, 1-10 parts of platycodon root, 1-10 parts of cassia twig, 1-5 parts of peach seed, 1-10 parts of tarragon, 1-5 parts of selfheal, 1-5 parts of coptis root and 1-10 parts of cassia seed;
the preparation method of the composition comprises the following steps:
(1) Decocting fructus Schisandrae chinensis, semen Persicae and semen Cassiae in water to obtain residue 1 and filtrate 1;
(2) Mixing the residue 1 with Alismatis rhizoma, cortex moutan, radix Platycodi, ramulus Cinnamomi, prunellae Spica and Coptidis rhizoma, and decocting in water to obtain filtrate 2;
(3) Decocting herba Artemisiae Scopariae and semen Platycladi in water to obtain filtrate 3;
(4) Concentrating filtrate 1, filtrate 2 and filtrate 3 to obtain concentrated solution;
wherein, soaking for 20-40min before decoction in the step (1); the decoction time is 0.5-1h, the decoction times are 1-2 times, and the mass ratio of the volume of water to the shizandra berry, the peach kernel and the cassia seed is 8-12:1mL/g;
Adding soybean phospholipid and sucrose ester into the water in the step (2), wherein the mass ratio of the soybean phospholipid to the sucrose ester to the water is 0.005-0.01:0.001-0.003:1, a step of; the decoction time is 1-1.5h, and the times of decoction are 1-2 times;
Steaming herba Artemisiae Scopariae and semen Platycladi in step (3) for 40-60min before decocting with water, wherein the temperature of steaming is 80-90deg.C.
2. The composition according to claim 1, wherein the raw materials of the composition are the following components in parts by weight: 1-5 parts of platycladi seed, 1-5 parts of shizandra berry, 1-5 parts of rhizoma alismatis, 3-6 parts of moutan bark, 2-6 parts of platycodon grandiflorum, 1-5 parts of cassia twig, 1-3 parts of peach seed, 1-5 parts of artemisia capillaris, 1-3 parts of selfheal, 1-3 parts of coptis chinensis and 1-5 parts of cassia seed.
3. The composition according to claim 1, wherein the raw materials of the composition are the following components in parts by weight: 2 parts of platycladi seed, 3 parts of shizandra berry, 5 parts of rhizoma alismatis, 5 parts of moutan bark, 5 parts of platycodon grandiflorum, 3 parts of cassia twig, 2 parts of peach seed, 5 parts of herba artemisiae capillaris, 1 part of selfheal, 1 part of coptis chinensis and 4 parts of cassia seed.
4. A process for the preparation of a composition as claimed in any one of claims 1 to 3, comprising the steps of:
(1) Decocting fructus Schisandrae chinensis, semen Persicae and semen Cassiae in water to obtain residue 1 and filtrate 1;
(2) Mixing the residue 1 with Alismatis rhizoma, cortex moutan, radix Platycodi, ramulus Cinnamomi, prunellae Spica and Coptidis rhizoma, and decocting in water to obtain filtrate 2;
(3) Decocting herba Artemisiae Scopariae and semen Platycladi in water to obtain filtrate 3;
(4) Concentrating filtrate 1, filtrate 2 and filtrate 3 to obtain concentrated solution;
wherein, soaking for 20-40min before decoction in the step (1); the decoction time is 0.5-1h, the decoction times are 1-2 times, and the mass ratio of the volume of water to the shizandra berry, the peach kernel and the cassia seed is 8-12:1mL/g;
Adding soybean phospholipid and sucrose ester into the water in the step (2), wherein the mass ratio of the soybean phospholipid to the sucrose ester to the water is 0.005-0.01:0.001-0.003:1, a step of; the decoction time is 1-1.5h, and the times of decoction are 1-2 times;
Steaming herba Artemisiae Scopariae and semen Platycladi in step (3) for 40-60min before decocting with water, wherein the temperature of steaming is 80-90deg.C.
5. Use of a composition according to any one of claims 1 to 3 for the preparation of a product for the treatment of hypertension.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210319473.2A CN116920029B (en) | 2022-03-29 | 2022-03-29 | Traditional Chinese medicine composition for treating hypertension and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210319473.2A CN116920029B (en) | 2022-03-29 | 2022-03-29 | Traditional Chinese medicine composition for treating hypertension and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116920029A CN116920029A (en) | 2023-10-24 |
| CN116920029B true CN116920029B (en) | 2024-05-17 |
Family
ID=88392725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210319473.2A Active CN116920029B (en) | 2022-03-29 | 2022-03-29 | Traditional Chinese medicine composition for treating hypertension and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116920029B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104435225A (en) * | 2014-09-29 | 2015-03-25 | 李中昕 | Traditional Chinese medicine for treating hypertension and preparation method of capsule thereof |
| CN104758495A (en) * | 2015-03-16 | 2015-07-08 | 关捷 | Traditional Chinese medicine composition for treating hypertension in the type of collateral retardation due to blood stasis |
| CN105381267A (en) * | 2015-11-09 | 2016-03-09 | 长葛市新世纪机电有限公司 | Traditional Chinese medicine composition for treating hypertension and oral preparation and preparation method thereof |
| CN107296914A (en) * | 2017-08-07 | 2017-10-27 | 石林星 | It is a kind of to treat Chinese medicine composition of hypertension and preparation method thereof |
| CN113499385A (en) * | 2021-08-31 | 2021-10-15 | 何彦生 | Traditional Chinese medicine formula for treating fatty liver |
-
2022
- 2022-03-29 CN CN202210319473.2A patent/CN116920029B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104435225A (en) * | 2014-09-29 | 2015-03-25 | 李中昕 | Traditional Chinese medicine for treating hypertension and preparation method of capsule thereof |
| CN104758495A (en) * | 2015-03-16 | 2015-07-08 | 关捷 | Traditional Chinese medicine composition for treating hypertension in the type of collateral retardation due to blood stasis |
| CN105381267A (en) * | 2015-11-09 | 2016-03-09 | 长葛市新世纪机电有限公司 | Traditional Chinese medicine composition for treating hypertension and oral preparation and preparation method thereof |
| CN107296914A (en) * | 2017-08-07 | 2017-10-27 | 石林星 | It is a kind of to treat Chinese medicine composition of hypertension and preparation method thereof |
| CN113499385A (en) * | 2021-08-31 | 2021-10-15 | 何彦生 | Traditional Chinese medicine formula for treating fatty liver |
Non-Patent Citations (3)
| Title |
|---|
| 桂枝茯苓方中桂枝、芍药的本草考证;谭保平;等;广西中医药;20141220;第37卷(第06期);第54-55页 * |
| 浅析肾气丸中牡丹皮的应用;杨梅;等;河南中医;20160630;第36卷(第06期);第942-944页 * |
| 祛瘀化浊法治疗高脂血症的临床观察;黄瑀, 等;中国中医药信息杂志;19000101;第08卷(第04期);第61-62页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116920029A (en) | 2023-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102772748B (en) | Traditional Chinese medicine preparation for treating liver-depression qi-stagnation type viral myocarditis and preparation method thereof | |
| EP1386614A1 (en) | Herbal pharmaceutical composition for treatment of hiv/aids patients | |
| CN105233202A (en) | Preparation method of drug for treating peptic ulcers and extractive prepared according to preparation method | |
| CN102631538B (en) | Traditional Chinese medicine for treating heart disease | |
| CN104587161A (en) | Traditional Chinese medicine composition for treating nephropathy of amylaidosis | |
| CN116920029B (en) | Traditional Chinese medicine composition for treating hypertension and preparation method thereof | |
| CN100428944C (en) | Compound traditional Chinese medicine for improving eyesight and its prepn. method | |
| CN105106872A (en) | Traditional Chinese medicine composition for treating coronary heart diseases and preparation method of traditional Chinese medicine composition | |
| CN102416121B (en) | Application of medicinal composition in preparation of medicaments for treating gastric ulcer | |
| CN108743887A (en) | Treat the Chinese medicine composition and preparation method thereof of liver fibrosis and hepatic sclerosis | |
| CN106334171A (en) | Traditional Chinese medicine preparation for repairing liver damage and preparation method thereof | |
| CN105727089A (en) | Application of medicine composition containing folium artemisiae argyi to preparing medicine for treating irritable bowel syndrome | |
| CN102430073B (en) | Medicinal composition for treating peptic ulcer | |
| CN104984268A (en) | Traditional Chinese medicine composition treating cerebral thrombosis and preparing method of traditional Chinese medicine composition | |
| CN101549140B (en) | Traditional Chinese medicine composition for treating AIDS and preparation method thereof | |
| CN104162090B (en) | Pharmaceutical composition and preparation method thereof | |
| CN111214584B (en) | Traditional Chinese medicine composition for tonifying kidney and benefiting liver as well as preparation method and application thereof | |
| CN102755580B (en) | Method for preparing chewable tablets of drug for treating unstable angina pectoris | |
| CN108186874B (en) | A Chinese medicinal composition for treating diabetes | |
| CN102416122B (en) | Application of medicinal composition in preparation of medicaments for treating duodenal ulcer | |
| CN105816819A (en) | Method for preparing traditional Chinese medicine composition for treating cerebral thrombosis | |
| CN105456933A (en) | Traditional Chinese medicine capable of activating blood to remove stasis and clearing and activating channels and collaterals and preparation method of traditional Chinese medicine | |
| CN104096212A (en) | Traditional Chinese medicine application for treating myocardial infarction and application for same | |
| CN105213537A (en) | A kind of pharmaceutical composition for the treatment of congestive heart failure | |
| CN104491602A (en) | Traditional Chinese medicine for treating chronic heart failure, premature beat and arrhythmia and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |